Private biotech market becoming frothy, says Sarissa's Alex Denner

Sarissa Capital Management’s Alex Denner explains why the private biotech market is becoming "quite frothy" amid the Covid-19 pandemic with CNBC's David Faber. The two spoke at the Active-Passive Investor Summit in New York City.